VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

Alpha Fetoprotein Plasmid DNA Vaccine
Vaccine Information
  • Vaccine Name: Alpha Fetoprotein Plasmid DNA Vaccine
  • Target Pathogen: Cancer
  • Target Disease: Cancer
  • Type: DNA vaccine
  • Status: Clinical trial
  • Host Species for Licensed Use: Human
  • Host Species as Laboratory Animal Model: Human
  • AFP gene engineering:
    • Type: DNA vaccine construction
    • Description:
    • Detailed Gene Information: Click Here.
  • Description: A vaccine consisting of plasmid DNA encoding alpha fetoprotein. After vaccination, expressed alpha fetoprotein may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells that express alpha fetoprotein, resulting in tumor cell lysis. (NCI05) (NCIT_C48373).
Host Response

Human Response

  • Host Strain: male, 80 years, Caucasian, HBV-/HCV-, with stage II HCC
  • Vaccination Protocol: This patient was vaccinated intramuscularly between 11/2010-2/2011. Before vaccination, patients received 650 mg acetaminophen and 50 mg diphenhydramine. For each of the three monthly plasmid injections, 2.5 mg of pAFP and 2.5 mg of pGM-CSF were mixed together in the syringes before injection. For the dose of 109 pfu of AdVhAFP, the virus was diluted in sterile saline in the IMCPL before preparing the syringe for injection (Butterfield et al., 2014).
  • Immune Response: This patient had a weak AFP-specific T cell response, a strong AdV-specific cellular response and recurred with an AFP-expressing HCC at nine months (Butterfield et al., 2014).
References
Butterfield et al., 2014: Butterfield LH, Economou JS, Gamblin TC, Geller DA. Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients. Journal of translational medicine. 2014; 12; 86. [PubMed: 24708667].
NCIT_C48373: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C48373]